Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Study of Response-Guided Therapy Following Neoadjuvant Endocrine Therapy to Optimize Adjuvant Treatment in Premenopausal HR+/HER2- Breast Cancer (JCOG2402, Young HOPE)

NCT07671885 is registered in ClinicalTrials.gov with Tokyo Women's Medical University as lead sponsor.

NCT NCT07671885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07671885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Study of Response-Guided Therapy Following Neoadjuvant Endocrine Therapy to Optimize Adjuvant Treatment in Premenopausal HR+/HER2- Breast Cancer (JCOG2402, Young HOPE)
Lead sponsor
Tokyo Women's Medical University
Phase
Phase 3
Overall status
Recruiting
Start date
January 28, 2026
Completion date
January 27, 2039
Enrollment
950 (estimated)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer